Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HRS-7085 in ulcerative colitis
CTR20253983Phase 2Active
- Sponsor
- Shandong Sende
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-7085 in autoimmune colitis, inflammatory bowel disease (IBD), sponsored by Shandong Sende. Started Oct 2025; status: active.
02
Drugs
HRS-7085
03
Conditions
autoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on CTR20253983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253983.